RxDoctor Payments Data

Chase Rudolph

Optometrist · Herrin, ILNPI 1457663809

Payments from drug & device makers

$6,143in general payments, 2019–2025

Across 234 payments — averaging $26.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • Bausch & Lomb Americas Inc.$1K
  • Johnson & Johnson Vision Care, Inc.$884
  • AbbVie$742
  • Coopervision Inc.$395
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$270
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$6,114100%
  • Entertainment$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,143 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.

See all optometrist providers in Illinois

Medicare billing

Part B allowed, 2024
$162,492
Medicare patients
769
Services billed
11,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast26$46,661
RestasisCyclosporine35$44,417
LumiganBimatoprost72$38,671
Cyclosporine12$9,673
VyzultaLatanoprostene Bunod15$6,412
Travatan ZTravoprost18$6,013
Fluorometholone87$5,423
CombiganBrimonidine Tartrate/Timolol17$5,040
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol44$5,020
Travoprost27$3,333
TafluprostTafluprost/Pf21$3,225
Latanoprost278$2,884
Loteprednol Etabonate22$2,842
Tobramycin-DexamethasoneTobramycin/Dexamethasone41$1,531
ValacyclovirValacyclovir Hcl19$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$742$88,128124 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$1,026$53,07341 claims
NovartisTravatan Z$177$6,01318 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$270$2,84222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,257 optometrist providers in Illinois.

Other optometrist in Herrin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →